Click image to view it in full size

As CGT moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. The migration from paper-based data to the digital format will connect individual patient supply chain data with individual patient clinical data and incorporate it into the overall analysis. Time and speed will become crucial factors to stay ahead of the competition and reap the resulting benefits. The success of CGT in prevalent diseases, such as diabetes and stroke, will be the game changer during the forecast period and lead to new industry access models. One strategy does not fit all in the CGT space; biopharma companies are focusing on partnerships with small-mid-size pharma companies to boost their pipelines and CDMOs are trying to build end-to-end CGT capabilities to support the burgeoning CGT pipeline. This Frost & Sullivan analysis examines the global cell and gene therapy (CGT) sector. It highlights revenue forecasts and key growth opportunities for CGT industry participants based on the evolution of their business models and strategic approaches as well as investments and regulations. The analysis segments the industry by product (cell therapy, gene-modified cell therapy, and gene therapy), and it also focuses on subsegments (allogeneic versus autologous; ex vivo versus in vivo). Industry forecasts run from 2022 through 2027, and they capture key industry developments, such as capacity expansion, mergers and acquisitions, and extension of services offerings set to impact overall CGT industry growth.